Insitro: Serafim Batzoglou
Serafim Batzoglou has become chief data officer of San Francisco-based drug discovery and development firm Insitro. He joins the company from Illumina, where he was VP of applied and computational biology. Prior to that, he was a professor of computer science at Stanford University. He is also a cofounder of DNAnexus. Batzoglou holds a PhD in computer science, a master's degree in electrical engineering, and a BS in mathematics and computer science from MIT.
Centogene: Philip Lambert, Peter Bauer
Philip Lambert has become CSO of Centogene, replacing Peter Bauer, who is now the firm's chief genomic officer. Lambert joins the company from Life Biosciences, where he was senior VP of discovery and labs as well as chief operating officer of two subsidiaries, Selphagy Therapeutics and Spotlight Biosciences. Prior to that, he was scientific partner and head of discovery at Charles River Laboratories. He also cofounded preclinical screening firm VivoPath. Lambert holds a PhD in neuropharmacology from Imperial College London and a BSc in pharmacology from the University of Liverpool.
NeoGenomics: Lawrence Weiss
NeoGenomics has appointed Lawrence Weiss as the company's chief medical officer, effective Nov. 25. He has been NeoGenomics' CSO since December 2018. Prior to that, he had been the firm's director of pathology services since March 2016. Before joining NeoGenomics, Weiss was a pathologist and later laboratory director at Clarient Diagnostic Services.
Bionano Genomics: Mike Ward
Bionano Genomics CFO Mike Ward has notified the firm of his resignation, effective Dec. 6. "Ward's resignation is not the result of any disagreement with the company," Bionano Genomics said last week in a document filed with the US Securities and Exchange Commission.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.